You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: May 17, 2025

Drug Sales Trends for VERAPAMIL


✉ Email this page to a colleague

« Back to Dashboard


Payment Methods and Pharmacy Types for VERAPAMIL (2021)

Revenues by Pharmacy Type

Pharmacy Type Revenues
MAIL-ORDER $7,037,451
INSIDE ANOTHER STORE $57,703,586
[disabled in preview] $88,704,722
This preview shows a limited data set
Subscribe for full access, or try a Trial

Units Sold by Pharmacy Type

Pharmacy Type Units
MAIL-ORDER 339,112
INSIDE ANOTHER STORE 837,181
[disabled in preview] 1,114,118
This preview shows a limited data set
Subscribe for full access, or try a Trial

Revenues by Payment Method

Payment Method Revenues
MEDICAID $2,982,281
MEDICARE $71,204,640
[disabled in preview] $79,258,839
This preview shows a limited data set
Subscribe for full access, or try a Trial
Drug Sales Revenue Trends for VERAPAMIL
Drug Units Sold Trends for VERAPAMIL

Market Analysis and Sales Projections for Verapamil

Introduction to Verapamil

Verapamil, a calcium channel blocker, is widely used in the treatment of hypertension, angina, and certain types of arrhythmias. The drug's efficacy and broad application have made it a significant player in the pharmaceutical market.

Market Size and Growth Projections

The Verapamil market has experienced rapid growth in recent years and is anticipated to continue this trend. Here are some key projections:

  • Global Market Value: The Verapamil market reached a value of USD billion in 2023 and is expected to attain USD billion by 2031, exhibiting robust growth rates throughout the forecast period[1][3].
  • Compound Annual Growth Rate (CAGR): The market is projected to grow at a CAGR of around 5.2% from 2023 to 2027, driven by increasing demand for cardiovascular drugs and rising incidences of hypertension and arrhythmias worldwide[4].

Market Segmentation

The Verapamil market is segmented based on several key factors:

By Type

  • Tablets: This is one of the most common forms of Verapamil, including ordinary and sustained-release tablets[3].
  • Capsules: Another form in which Verapamil is available.
  • Injection: Used for acute conditions requiring immediate action.
  • Others: Includes other formulations and delivery methods[1].

By Application

  • Hospital Pharmacy: A significant segment due to the drug's use in treating acute conditions.
  • Retail Pharmacy: Where patients can purchase the drug for chronic conditions.
  • Online Sales: Growing due to the convenience and cost advantages of e-commerce channels.
  • Others: Includes clinics, research institutions, and other healthcare settings[1][3].

By Geography

  • North America: Expected to play a pivotal role in the market's development, driven by advanced technology and the presence of major industry players[4].
  • Europe: Anticipated to experience significant growth with a strong CAGR during the forecast period.
  • Asia-Pacific: A rapidly growing market due to increasing healthcare needs and economic growth.
  • South America and Middle-East & Africa: Also expected to contribute to the global growth, though at a slower pace compared to North America and Europe[1][3].

Market Dynamics

Drivers

  • Increasing Demand for Cardiovascular Drugs: Rising incidences of hypertension and arrhythmias globally are driving the demand for Verapamil[4].
  • Advancements in Distribution Channels: The rise of e-commerce and direct-to-consumer (D2C) sales channels has made the drug more accessible and convenient for consumers[4].

Restraints

  • Competition: The market is highly competitive, with several manufacturers vying for market share.
  • Regulatory Challenges: Strict regulatory environments can impact the approval and marketing of new formulations.

Opportunities

  • Emerging Markets: Growing healthcare needs in regions like Asia-Pacific and South America present significant opportunities for expansion.
  • Innovative Formulations: Developing new and more effective formulations can help companies gain a competitive edge.

Challenges

  • Economic Factors: Economic downturns can affect consumer spending on pharmaceuticals.
  • Side Effects and Safety Concerns: Like any medication, Verapamil has side effects, and safety concerns can impact market growth[1][3][4].

Key Players

The Verapamil market is dominated by several key players, including:

  • Abbott Laboratories
  • Mylan
  • Replek Farm
  • YUNGSHIN PHARM IND. CO. LTD
  • The Central Pharmaceutical CO. Ltd. Tianjin
  • Bharat Pharmaceuticals
  • Titan Pharma (India) Pvt Ltd
  • Vpl Chemicals Pvt Ltd
  • Wuhan Fortuna Chemical Co., Ltd[1][4].

Sales Projections

Revenue

  • The global Verapamil Hydrochloride market is expected to reach USD 2.5 billion by 2027, growing at a CAGR of 5.2% from 2023 to 2027[4].

Units Sold

  • While exact unit sales figures are not publicly available, the increasing revenue indicates a corresponding rise in the number of units sold across various pharmacy types and distribution channels[5].

Regional Outlook

North America

  • This region is expected to continue playing a pivotal role in the market's development, driven by the high adoption of advanced technology and the presence of major industry players[4].

Europe

  • Europe is anticipated to experience significant growth with a strong CAGR during the forecast period, driven by similar factors as North America[4].

Asia-Pacific

  • This region is rapidly growing due to increasing healthcare needs and economic growth, making it a promising market for Verapamil[1][3].

E-Commerce and Direct-to-Consumer Channels

The rise of e-commerce and D2C sales channels has significantly transformed the distribution landscape for Verapamil. These channels offer cost advantages and a more personalized purchasing experience, expanding the market reach and providing greater consumer access to the drug[4].

Key Takeaways

  • The Verapamil market is poised for significant growth driven by increasing demand for cardiovascular drugs.
  • The market is segmented by type, application, and geography, with North America and Europe leading the growth.
  • Key players are focusing on innovative formulations and expanding distribution channels.
  • E-commerce and D2C channels are becoming increasingly important for market growth.

FAQs

What is the projected growth rate of the Verapamil market from 2023 to 2027?

The Verapamil market is projected to grow at a CAGR of around 5.2% from 2023 to 2027[4].

Which regions are leading the Verapamil market?

North America and Europe are expected to lead the market, with Asia-Pacific also showing significant growth potential[1][3][4].

What are the main drivers of the Verapamil market?

The main drivers include increasing demand for cardiovascular drugs and the rise of e-commerce and D2C sales channels[4].

Who are the key players in the Verapamil market?

Key players include Abbott Laboratories, Mylan, Replek Farm, YUNGSHIN PHARM IND. CO. LTD, and others[1][4].

How is the rise of e-commerce affecting the Verapamil market?

The rise of e-commerce is making the drug more accessible and convenient for consumers, expanding market reach and providing cost advantages[4].

Sources

  1. Market Research Intellect, "Global Verapamil Market Size, Scope And Forecast Report", October 2024.
  2. Market Research Reports, "Verapamil - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030", November 15, 2024.
  3. Market Research Intellect, "Verapamil Hydrochloride Tablets Market Size, Scope And Forecast Report", December 2024.
  4. Verified Market Reports, "Global Verapamil Hydrochloride Market E-Commerce and Direct-to-Consumer, Sustainability", December 27, 2024.
  5. DrugPatentWatch, "VERAPAMIL historic drug sales".
Last updated: 2024-12-31

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.